BP-1-102

Name: BP-1-102
Brand: MedChemExpress
SKU: HY-100493
Rating: 5.0 (11 reviews)

Cat. No.: HY-100493 Pureza: 99.26%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1334493-07-0

Tamaño	Stock	Cantidad

Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
250 mg	En stock	Estimated Time of Arrival: December 31
500 mg	En stock	Estimated Time of Arrival: December 31
1 g	Obtener un presupuesto
5 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 11 publication(s) in Google Scholar

Other Forms of BP-1-102:

BP-1-102 (Standard) Obtener un presupuesto

11 Publications Citing Use of MCE BP-1-102

: BP-1-102 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2020 Jul 8;18(1):104. [Abstract]; Immunoblotting analysis of pulmonary STAT3 and pY-STAT3 in mice 24 h after CLP with BP-1-102 (BP) administration. BP downregulates the elevated pY-STAT3 level in the mouse lung 24 h after CLP.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas STAT:

Ver todas las isoformas

STAT3 STAT5 STAT6 STAT1

Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

IC₅₀ & Target^[1]

STAT3

6.8 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	4.4 3 Compound: 1d; BP-1-102	Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis	[PMID: 35476936]
143B	IC₅₀	4.17 3 Compound: 1d; BP-1-102	Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay	[PMID: 35476936]
143B	IC₅₀	4.17 3 Compound: 1d; BP-1-102	Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay	[PMID: 35476936]
143B	IC₅₀	4.4 3 Compound: 1d; BP-1-102	Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis	[PMID: 35476936]
143B	IC₅₀	4.4 3 Compound: 1d; BP-1-102	Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis Antiinvasive activity against human 143B cells assessed as reduction in cell invasion measured after 12 hrs by crystal violet staining based inverted microscopic analysis	[PMID: 35476936]
143B	IC₅₀	4.17 3 Compound: 1d; BP-1-102	Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay Antimigratory activity against human 143B cells assessed as reduction in cell migration measured after 12 hrs by wound healing assay	[PMID: 35476936]
143B	IC₅₀	5.87 3 Compound: 1d; BP-1-102	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
143B	IC₅₀	5.87 3 Compound: 1d; BP-1-102	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
143B	IC₅₀	5.87 3 Compound: 1d; BP-1-102	Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human 143B cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
A549	IC₅₀	5 3 Compound: 3; SH4-54	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 34000483]
A549	IC₅₀	5 3 Compound: 3; SH4-54	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 34000483]
DU-145	EC₅₀	22.7 3 Compound: 17o	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	[PMID: 21788134]
DU-145	EC₅₀	22.7 3 Compound: 17o	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	[PMID: 21788134]
DU-145	EC₅₀	22.7 3 Compound: 17o	Cytotoxicity against human DU145 cells after 72 hrs by MTS assay Cytotoxicity against human DU145 cells after 72 hrs by MTS assay	[PMID: 21788134]
DU-145	IC₅₀	23 3 Compound: 9, BP-1-102	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
DU-145	IC₅₀	23 3 Compound: 9, BP-1-102	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
DU-145	IC₅₀	23 3 Compound: 9, BP-1-102	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
HCT-116	IC₅₀	15.05 3 Compound: BP-1-102; 36	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29674294]
HCT-116	IC₅₀	15.05 3 Compound: BP-1-102; 36	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29674294]
HCT-116	IC₅₀	15.05 3 Compound: BP-1-102; 36	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29674294]
HOS	IC₅₀	6.44 3 Compound: 1d; BP-1-102	Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
HOS	IC₅₀	6.44 3 Compound: 1d; BP-1-102	Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
JJN-3	EC₅₀	16.7 3 Compound: 17o	Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay	[PMID: 21788134]
HOS	IC₅₀	6.44 3 Compound: 1d; BP-1-102	Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
JJN-3	EC₅₀	16.7 3 Compound: 17o	Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay	[PMID: 21788134]
MDA-MB-231	IC₅₀	6.8 3 Compound: 14; BP-1-102	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28245116]
JJN-3	EC₅₀	16.7 3 Compound: 17o	Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay Cytotoxicity against human JJN-3 cells after 72 hrs by MTS assay	[PMID: 21788134]
MDA-MB-231	IC₅₀	2 3 Compound: 3; SH4-54	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 34000483]
MDA-MB-231	IC₅₀	2 3 Compound: 3; SH4-54	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 34000483]
MDA-MB-468	EC₅₀	10.9 3 Compound: 17o	Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay	[PMID: 21788134]
MDA-MB-231	IC₅₀	6.8 3 Compound: 14; BP-1-102	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28245116]
MDA-MB-468	IC₅₀	11 3 Compound: 9, BP-1-102	Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
MDA-MB-231	IC₅₀	6.8 3 Compound: 14; BP-1-102	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 28245116]
MDA-MB-468	EC₅₀	10.9 3 Compound: 17o	Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay	[PMID: 21788134]
MDA-MB-468	EC₅₀	10.9 3 Compound: 17o	Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells after 72 hrs by MTS assay	[PMID: 21788134]
MG-63	IC₅₀	12.66 3 Compound: 1d; BP-1-102	Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
MDA-MB-468	IC₅₀	11 3 Compound: 9, BP-1-102	Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
MDA-MB-468	IC₅₀	11 3 Compound: 9, BP-1-102	Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human MDA468 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
OCI-AML2	IC₅₀	10 3 Compound: 9, BP-1-102	Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
MG-63	IC₅₀	12.66 3 Compound: 1d; BP-1-102	Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
MG-63	IC₅₀	12.66 3 Compound: 1d; BP-1-102	Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay Antiproliferative activity against human MG-63 cells assessed as inhibition of cell growth incubated for 48 hrs by cell titer based MTS assay	[PMID: 35476936]
U2OS	IC₅₀	8.3 3 Compound: 14; BP-1-102	Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay	[PMID: 28245116]
MGC-803	IC₅₀	5.6 3 Compound: 3; SH4-54	Antiproliferative activity against human MGC-803 cells Antiproliferative activity against human MGC-803 cells	[PMID: 34000483]
MGC-803	IC₅₀	5.6 3 Compound: 3; SH4-54	Antiproliferative activity against human MGC-803 cells Antiproliferative activity against human MGC-803 cells	[PMID: 34000483]
OCI-AML2	IC₅₀	10 3 Compound: 9, BP-1-102	Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
OCI-AML2	IC₅₀	10 3 Compound: 9, BP-1-102	Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against human OCI-AML2 cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 23968501]
U2OS	IC₅₀	8.3 3 Compound: 14; BP-1-102	Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay	[PMID: 28245116]
U2OS	IC₅₀	8.3 3 Compound: 14; BP-1-102	Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay Antiproliferative activity against human U2OS cells after 24 hrs by MTT assay	[PMID: 28245116]

In Vitro

BP-1-102 binds Stat3 with an affinity K_D of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro, with an IC₅₀ value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas^[2]. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

626.59

Fòrmula

C₂₉H₂₇F₅N₂O₆S

No. CAS

1334493-07-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(=O)(C4=C(F)C(F)=C(F)C(F)=C4F)=O)=O)C=C1O

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvente y solubilidad

In Vitro:

DMSO : ≥ 33 mg/mL (52.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5959 mL	7.9797 mL	15.9594 mL
5 mM	0.3192 mL	1.5959 mL	3.1919 mL
10 mM	0.1596 mL	0.7980 mL	1.5959 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.26%

Select Batch:

Ficha de datos (277 KB) SDS (393 KB)

COA (251 KB) HNMR (283 KB) LCMS (102 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8. [Content Brief]

[2]. De Simone V, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015 Jul;34(27):3493-503. [Content Brief]

Ensayo celular ^[1]	Proliferating cells in 6- or 96-well plates are treated once with 0-30 μM BP-1-102 for 24 h or with 10 μM BP-1-102 for up to 96 h. Viable cells are counted by trypan blue exclusion/phase-contrast microscopy or assessed by a cell proliferation kit^[1]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Administraciòn de animales ^[1]	Mice: Athymic nude mice with established tumors are grouped and then given BP-1-102 (in 0.05% DMSO in water) at 1 or 3mg/kg (i.v.) every 2 or every 3 d or 3 mg/kg (oral gavage, 100 μL) every day for 15 or 20 d. Animals are monitored every day, and tumor sizes are measured with calipers and body weights are taken every 2 or 3 d. For each treatment group, the tumor volumes for each set of measurements are statistically analyzed in comparison with the control group using a paired T test^[1]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Referencias	[1]. Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8. [Content Brief] [2]. De Simone V, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015 Jul;34(27):3493-503. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.5959 mL	7.9797 mL	15.9594 mL	39.8985 mL
	5 mM	0.3192 mL	1.5959 mL	3.1919 mL	7.9797 mL
	10 mM	0.1596 mL	0.7980 mL	1.5959 mL	3.9898 mL
	15 mM	0.1064 mL	0.5320 mL	1.0640 mL	2.6599 mL
	20 mM	0.0798 mL	0.3990 mL	0.7980 mL	1.9949 mL
	25 mM	0.0638 mL	0.3192 mL	0.6384 mL	1.5959 mL
	30 mM	0.0532 mL	0.2660 mL	0.5320 mL	1.3299 mL
	40 mM	0.0399 mL	0.1995 mL	0.3990 mL	0.9975 mL
	50 mM	0.0319 mL	0.1596 mL	0.3192 mL	0.7980 mL

BP-1-102 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BP-1-1021334493-07-0STATInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Nombre del producto			Requested Quantity *
Nombre del solicitante *			Saludo
Direcciòn del E-mail *			Número de teléfono *
Department			Nombre de la Organizaciòn *
City			Provincia
Country or Region *
Observaciones

Nombre del producto			Lot #
Nombre del solicitante *			Direcciòn del E-mail *
Número de teléfono			Department *
Nombre de la Organizaciòn *			Country or Region *
Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

BP-1-102

Revisión del cliente

Other Forms of BP-1-102:

BP-1-102 Related Antibodies

11 Publications Citing Use of MCE BP-1-102

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas STAT:

Actividad biológica

Protocolo

Pureza y Documentación

Referencias

Revisión del cliente

BP-1-102 Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

BP-1-102 Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report